Racial disparities in the treatment of metastatic pancreatic cancer using 5-fluorouracil (5-FU) vs. gemcitabine-based combination chemotherapy: A single-institutional analysis.

Authors

Sowbharnika Arivazhagan, Baton Rouge General Medical Center
Aneesha Ananthula, LSU Health Sciences Center - New Orleans
Julijana Zoran Conic, LSU Health Sciences Center - New OrleansFollow
Lily Zhiying Chen, LSU Health Sciences Center - New OrleansFollow
ConnerDaniel Hartupee, LSU Health Sciences Center - New OrleansFollow
Xena Xiaoshu Zheng, LSU Health Sciences Center - New Orleans
Brandi Liang Sun, LSU Health Sciences Center - New OrleansFollow
Conner Steven Pate, LSU Health Sciences Center - New OrleansFollow
Andrew G. Chapple, LSU Health Sciences Center - New OrleansFollow
Rajasree Pia Chowdry, LSU Health Sciences Center - New OrleansFollow

Document Type

Conference Proceeding

Publication Date

5-31-2023

Publication Title

Journal of Clinical Oncology

Abstract

2023 American Society of Clinical Oncology Annual Meeting, ASCO, June 2 - 6, 2023, Chicago, IL

First Page

e16292

Volume

41

Publisher

American Society of Clinical Oncology

Comments

Abstract Number: e16292

ISBN

0732183X

Recommended Citation

Arivazhagan, Sowbharnika; Ananthula, Aneesha; Conic, Julijana Zoran; Chen, Lily Zhiying; Hartupee, ConnerDaniel; Zheng, Xena Xiaoshu; Sun, Brandi Liang; Pate, Conner Steven; Chapple, Andrew G.; and Chowdry, Rajasree Pia, "Racial disparities in the treatment of metastatic pancreatic cancer using 5-fluorouracil (5-FU) vs. gemcitabine-based combination chemotherapy: A single-institutional analysis." (2023). School of Medicine Faculty Publications. 2372.
https://digitalscholar.lsuhsc.edu/som_facpubs/2372
10.1200/JCO.2023.41.16_suppl.e16292